Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 11/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.33 |
| ▸ | AURKA | O14965 | 5/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392536 | 1.00 | TYK2 (0.38) | TYK2PDE4DAURKAKDM1AHPGDS | |
| SCHEMBL30392913 | 0.94 | TYK2 (0.33) | TYK2PDE4DAURKAKDM1ANPC1 | |
| SCHEMBL30392105 | 0.94 | TYK2 (0.33) | TYK2PDE4DAURKAKDM1ANPC1 | |
| SCHEMBL26098951 | 0.94 | TYK2 (0.33) | TYK2PDE4DAURKAKDM1ANPC1 | |
| SCHEMBL26100963 | 0.92 | TYK2 (0.40) | TYK2PDE4DHPGDS | |
| SCHEMBL30392501 | 0.91 | TYK2 (0.41) | TYK2PDE4D | |
| SCHEMBL26102625 | 0.91 | TYK2 (0.41) | TYK2PDE4D | |
| SCHEMBL26101565 | 0.91 | TYK2 (0.39) | TYK2PDE4DAURKAHPGDS | |
| SCHEMBL30392681 | 0.91 | TYK2 (0.33) | TYK2PDE4DAURKANPC1RAB9A | |
| SCHEMBL26101647 | 0.91 | TYK2 (0.33) | TYK2PDE4DAURKANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | TYK2 1/4885PDE4D 4649/4885AURKA 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.